Status:
UNKNOWN
Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
Guangzhou Burning Rock Dx Co., Ltd.
Conditions:
Lymphoma
Eligibility:
All Genders
40-75 years
Brief Summary
ASCEND-LYM is a prospective, multi-center, observational study aimed at detecting early stage lymphoma and constrcuting prognostic model by combined assays of cfDNA methylation and other biomarkers. T...
Eligibility Criteria
Inclusion
- Inclusion Criteria for All Participants:
- Age 40-75 years at the day of consenting to the study.
- Able to provide a written informed consent.
- Additional Inclusion Criteria for Cancer Participants:
- No prior cancer treatment (local or systematic) prior to blood draw.
- High suspicious or pathologically confirmed lymphoid malignancies within 42 days prior to blood draw.
- Additional Inclusion Criteria for Benign Disease Participants:
- No prior radical treatment of the benign diseases prior to study blood draw
- Pathologically confirmed diagnosis of lymphoid benign diseases within 90 days prior to blood draw.
- Exclusion Criteria for All Participants:
- Insufficient qualified blood samples.
- During pregnancy or lactation.
- Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
- Recipient of blood transfusion within 7 days prior to blood draw.
- Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw, such as rheumatic drugs (methotrexate, cyclophosphamide, or azathioprine), or endocrine drugs (tamoxifen).
- Additional Exclusion Criteria for Cancer Participants:
- With other known malignant tumors or multiple primary tumors.
- Lymphoid malignancies unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw.
- Additional Exclusion Criteria for Benign Disease Participants:
- With other known malignant tumors or comfirmed lymphoid malignancies.
- Lymphoid benign diseases unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw.
Exclusion
Key Trial Info
Start Date :
May 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
493 Patients enrolled
Trial Details
Trial ID
NCT05275036
Start Date
May 31 2022
End Date
August 31 2025
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SunYat-sen university cancer center
Guangzhou, China